An experienced attorney from the law firm of Reich & Binstock, which operates in all 50 states, can be a valuable asset to a plaintiff involved in a product liability lawsuit against a corporate behemoth. In litigation centered on the side effects of the combination oral contraceptive Yaz/Yasmin, one plaintiff’s plight is a sobering reminder of what a difference an attorney can make.
A plaintiff in a Yaz lawsuit against the pharmaceutical giant Bayer represented herself as she filed a motion to remand her case from the U.S. District Court for the Southern District of Illinois to the court from which a Washington-based judicial panel transferred the case, the federal trial court for the Northern District of Georgia.
“In seeking remand, plaintiff contends that the transferee judge, the Honorable David R.
Herndon, is biased against her, and that lead defense counsel has lied on the record and defamed her,” according to the U.S. Judicial Panel on Multidistrict Litigation, the entity that transferred the case to Illinois and that April 1 denied plaintiff’s motion to revert to Georgia.
In March, before the night that the lights went out in Georgia, the judge dismissed the case because the plaintiff failed to comply with a case management order. Her motion for remand was not considered moot because she had filed motions for relief since the dismissal.
What a mess.
Plaintiff’s case should have been about personal injury associated with the increased risks of Yaz/Yasmin. And this would have been so if she had called Reich & Binstock Founding Partner Robert Binstock, who has settled more than 100 Yaz cases.
An attorney can make a world of difference, especially one such as Binstock, who has 30 years of experience and a proven track record in litigation against pharmaceutical corporations.
Yaz/Yasmin patients who have suffered severe side effects may be entitled to compensation. The U.S. Food and Drug Administration approved those prescription drugs to prevent pregnancy, to treat premenstrual dysphoric disorder, and to treat moderate acne in patients at least 14 years old.
Adverse reactions associated with the use of these drugs include:
•· Blood clots
•· Venous thromboembolism (VTE)
•· Deep vein thrombosis (DVT)
•· Pulmonary embolism (PE)
•· Heart attack
What a pity so many patients did not know about the risks – risks allegedly the manufacturer should have known and warned about – before it was too late.
The U.S. Food and Drug Administration originally approved Yaz in 2001, according to the combination oral contraceptive’s prescribing information. It was not until April 2012 that the FDA approved the manufacturer’s new “warnings and precautions.” Since then, the new Yaz/Yasmin label would read, “Based on presently available information on Yasmin, DRSP-containing COCs may be associated with a higher risk of venous thromboembolism than COCs containing the progestin levonorgestrel or some other progestins…”
Patients who used Yaz and who since have suffered venous thromboembolism, deep vein thrombosis, pulmonary embolism, stroke or heart attack do not need to go it alone. They can contact Reich & Binstock for a free consultation.